ANL earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -8.19. Updated 2026-07-23.
Adlai Nortye (ANL) Research Hub
Adlai Nortye (ANL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 15.21 USD (+3.47%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.19, market cap 0.68B. This hub links to the full technical, earnings and options research available for ANL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.21 USD (+3.47%) |
| 52-week range | 8.54 USD – 16.12 USD |
| Trend regime | Range |
| 14-day RSI | 61.3 (Bullish) |
| Trailing P/E | -8.19 |
| Market cap | 0.68B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ANL
Covered Call on ANL: how it works, illustrative setup around the real 15.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANL: how it works, illustrative setup around the real 15.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANL: how it works, illustrative setup around the real 15.21 USD price, max profit/loss, breakeven and when to use it. Educational.
ANL technical analysis: range, last 15.21 USD, RSI 61.3, 52w range 8.54 USD–16.12 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ANL in?
Adlai Nortye (ANL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ANL in an uptrend or downtrend?
As of 2026-09-11, ANL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANL's trailing P/E ratio?
ANL's trailing P/E is -8.19, with a market cap of 0.68B. See the earnings research page for full valuation detail.
When does ANL next report earnings?
ANL is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.13333 USD.